Review Article
Accumulation of Mast Cells in the Lesions and Effects of Antiallergic Drugs on the Patients with Inflammatory Bowel Disease
Table 1
Basic pharmacological activity of IPD.
| (A) Immunomodulating activity | | (1) Suppression of IgE antibody production (murine, cultured human cell) | | (2) Suppression of Th2 cytokine production (murine, human cell) | | (3) Suppression of thymus and activation-regulated chemokine (TARC) production | | (4) Modulation of toll-like receptors 2 and 4 on antigen-presenting cells in rats | | (5) Augmentation of aging-induced downregulated IgE production in mice | | (B) Anti-inflammatory activity | | (1) Inhibition of histamine release from rat mast cells | | (2) Inhibition of murine eosinophil chemotaxis | | (3) Inhibition of EG2 positive eosinophil and CD4 or CD25 positive T-cell accumulation in human airway | | (4) Inhibition of human eosinophil degranulation | | (5) Inhibition of IL-4 induced vascular cell adhesion molecule 1 (VCAMI) expression on human umbilical vein endothelial cells | | (C) Experimental asthma | | (1) Inhibition of air-flow limitation (mice, guinea pigs) | | (2) Inhibition of airway hyperresponsiveness (mice, guinea pigs) | | (3) Inhibition of goblet-cell metaplasia of mice airway epithelium | |
|
|